Celsion Corporation announced results from its dose escalating phase IB OVATION I trial evaluating neoadjuvant chemotherapy treatment for six cycles and GEN-1 given weekly for a total of eight doses prior to interval debulking surgery in newly diagnosed patients with stage III/IV ovarian cancer.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
